• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Treatment of peritonitis due to continuous ambulatory peritoneal dialysis using a single daily intraperitoneal dose of 1g cefotiam].

作者信息

Ragnaud J M, Roche-Bezian M C, Marceau C, Demothes-Mainard F, Albin H, Prevost D, Wone C

出版信息

Pathol Biol (Paris). 1986 May;34(5):512-6.

PMID:3534734
Abstract

Peritonitis remains the main complication of CAPD. This study demonstrates that most cases can be successfully treated with cefotiam. In 17 patients under CAPD, 33 cases of bacterial peritonitis were observed, with clinical manifestations in 28. The mean cell count in peritoneal dialysis fluid was 2 820/mm3, with 2 200/mm3 polymorphonuclear leukocytes. Causative pathogens were Staphylococcus in 18 cases, Streptococcus in 4, Stomatococcus mucilaginous in 1, Corynebacterium J.K. in 1, Enterobacter in 3, Acinetobacter in 3 and Pseudomonas in 2. Two cultures were negative. First choice treatment was a daily intraperitoneal injection of 1 g cefotiam. 68.80% of patients recovered within 6 days. Failures were due to a methicillin-resistant Staphylococcus epidermidis in 3 cases, a relapsing Stomatococcus mucilaginous infection in 1, a Streptococcus faecalis in 1, an Acinetobacter in 3 and a Pseudomonas in 2. Mean cefotiam concentrations 24 hours after the intraperitoneal injection were 9.4 +/- 7.0 micrograms/ml (range 1.3-26.4 micrograms/ml) in serum and 3.4 +/- 3.3 micrograms/ml (range 0.4-12.2 micrograms/ml) in dialysate. These concentrations are greater than most of cefotiam's MICs for susceptible bacteria, a finding that confirms the value of treatment with a single daily intraperitoneal injection of cefotiam.

摘要

相似文献

1
[Treatment of peritonitis due to continuous ambulatory peritoneal dialysis using a single daily intraperitoneal dose of 1g cefotiam].
Pathol Biol (Paris). 1986 May;34(5):512-6.
2
[Treatment of peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal ceftriaxone].
Pathol Biol (Paris). 1988 May;36(5):552-6.
3
[Treatment of peritonitis under continuous ambulatory peritoneal dialysis using intraperitoneal ceftazidime].[持续非卧床腹膜透析时腹腔内使用头孢他啶治疗腹膜炎]
Pathol Biol (Paris). 1989 Jun;37(5 Pt 2):681-4.
4
[Transperitoneal resorption of cefotiam in CAPD patients with and without peritonitis].[伴有和不伴有腹膜炎的持续性非卧床腹膜透析患者中头孢替安的经腹膜吸收情况]
Med Klin (Munich). 1994 Sep 15;89(9):464-8.
5
[Evaluation of the epidemiological, clinical and laboratory findings in continuous ambulatory peritoneal dialysis related peritonitis attacks].[持续性非卧床腹膜透析相关性腹膜炎发作的流行病学、临床及实验室检查结果评估]
Mikrobiyol Bul. 2008 Apr;42(2):255-64.
6
Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.在接受持续性非卧床腹膜透析和持续性循环腹膜透析的终末期肾病患者中,使用大剂量腹腔内氨基糖苷类药物治疗腹膜炎。
Adv Perit Dial. 2000;16:280-4.
7
Changes in the organisms of resistant peritonitis in patients on continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析患者耐药性腹膜炎患者机体的变化。
Adv Perit Dial. 2004;20:52-7.
8
Acinetobacter peritonitis in patients receiving continuous ambulatory peritoneal dialysis.接受持续性非卧床腹膜透析患者的不动杆菌腹膜炎
South Med J. 1991 May;84(5):607-10.
9
Pharmacokinetics and bactericidal activity of a single daily dose of netilmicin in the treatment of CAPD-associated peritonitis.每日单次剂量奈替米星治疗连续性非卧床腹膜透析相关性腹膜炎的药代动力学及杀菌活性
Int J Clin Pharmacol Ther. 1996 Nov;34(11):465-9.
10
[Pharmacokinetics of vancomycin in chronic renal failure patients in continuous ambulatory peritoneal dialysis (CAPD) after intra-abdominal administration].[腹腔内给药后持续非卧床腹膜透析(CAPD)慢性肾衰竭患者万古霉素的药代动力学]
Pathol Biol (Paris). 1985 Jun;33(5 Pt 2):542-4.